Synapse

← BJC Reports

Papers in BJC Reports

Page 4 · newest first

  1. Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001–2020)BJC Reports · 2024
  2. Small extracellular vesicles as biomarkers of response in recurrent/metastatic HNSCC patients treated with immunotherapyBJC Reports · 2024
  3. Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A studyBJC Reports · 2024
  4. Cannabidiol and fluorinated derivative anti-cancer properties against glioblastoma multiforme cell lines, and synergy with imidazotetrazine agentsBJC Reports · 2024
  5. The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy?BJC Reports · 2024
  6. Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohortBJC Reports · 2024
  7. Towards replicability and sustainability in cancer researchBJC Reports · 2024
  8. Calcium intake and genetic variants in the calcium sensing receptor in relation to colorectal cancer mortality: an international consortium study of 18,952 patientsBJC Reports · 2024
  9. Temporal evolution and inter-patient heterogeneity in primary and recurrent head and neck squamous cell carcinomaBJC Reports · 2024
  10. Estimating cure proportion in cancer clinical trials using flexible parametric cure modelsBJC Reports · 2024
  11. Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancerBJC Reports · 2024
  12. Chromosomal copy number based stratification of gastric cancer has added prognostic value to Lauren’s histological classificationBJC Reports · 2024
  13. Retrospective evaluation of plasma protein tumour markers for early lung cancer detectionBJC Reports · 2024
  14. The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysisBJC Reports · 2024
  15. Alternative cancer clinics’ use of Google listings and reviews to mislead potential patientsBJC Reports · 2024
  16. Source credibility: a necessary North Star in cancer careBJC Reports · 2024
  17. Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumorsBJC Reports · 2024
  18. BOADICEA model: updates to the BRCA2 breast cancer risks for ages 60 years and olderBJC Reports · 2024
  19. System transferability of Raman-based oesophageal tissue classification using modern machine learning to support multi-centre clinical diagnosticsBJC Reports · 2024
  20. Ropeginterferon alfa-2b shows anti-polycythaemia vera activity without causing clinically significant anaemiaBJC Reports · 2024
  21. Accuracy of ultrasound, magnetic resonance imaging and intraoperative frozen section in the diagnosis of ovarian tumours: data from a London tertiary centreBJC Reports · 2024
  22. Climate change advocacy and cancer clinical trial organisationsBJC Reports · 2024
  23. A novel colorectal cancer test combining microsatellite instability and BRAF/RAS analysis: Clinical validation and impact on Lynch syndrome screeningBJC Reports · 2024
  24. Determining the efficacy of ExThera Seraph100 blood filtration in patients diagnosed with pancreatic cancer through the liquid biopsyBJC Reports · 2024
  25. Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of responseBJC Reports · 2024
  26. Design issues with lutetium-177 PSMA-617 registration studies that bias the outcome of the experimental arm reflect an increasing misalignment of contemporary oncology trials with true patient benefitBJC Reports · 2024
  27. Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancerBJC Reports · 2024
  28. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analysesBJC Reports · 2024
  29. Malignant peritoneal mesothelioma interactome with 417 novel protein–protein interactionsBJC Reports · 2024
  30. New light on chemotherapy toxicity and its preventionBJC Reports · 2024
  31. The association between being breastfed in infancy and risks of cancer in adulthood—a UK Biobank studyBJC Reports · 2024
  32. Progression of chronic liver disease to hepatocellular carcinoma: implications for surveillance and managementBJC Reports · 2024
  33. Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasisBJC Reports · 2024
  34. Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settingsBJC Reports · 2024
  35. Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?BJC Reports · 2024
  36. New insights into macrophage polarization and its prognostic role in patients with colorectal cancer liver metastasisBJC Reports · 2024
  37. The natural history of neurolymphomatosisBJC Reports · 2024
  38. Viruses in glioblastoma: an update on evidence and clinical trialsBJC Reports · 2024
  39. A practice changing paper: biallelic inactivation of BRCA2 in Fanconi anaemiaBJC Reports · 2024
  40. Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitorsBJC Reports · 2024
  41. Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN projectBJC Reports · 2024
  42. High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoidsBJC Reports · 2024
  43. Characterizing functional DNA damage and response caused by the combination of CHK1 and WEE1 inhibitors in ovarian and breast cancer modelsBJC Reports · 2024
  44. Penetrance estimates of hereditary cancers in a population setting using UK Biobank dataBJC Reports · 2024
  45. Single cell atlas of kidney cancer endothelial cells reveals distinct expression profiles and phenotypesBJC Reports · 2024
  46. Weight, weight gain and behavioural risk factors in women attending a breast cancer family history, risk and prevention clinic: an observational studyBJC Reports · 2024
  47. Racial and socioeconomic disparities in survival improvement of eight cancersBJC Reports · 2024
  48. Climate change: why oncologists need to get involvedBJC Reports · 2024
  49. Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancerBJC Reports · 2024
  50. Founder pathogenic variants in colorectal neoplasia susceptibility genes in Ashkenazi Jews undergoing colonoscopyBJC Reports · 2024